Cionic Neural Sleeve 2: FDA Cleared AI Powered Wearable for Neurological Mobility Disorders

The first and only FDA cleared wearable that simultaneously activates muscle movement and relaxes spasticity, using AI powered functional electrical stimulation embedded in a full leg garment to restore walking ability for people with multiple sclerosis, cerebral palsy, stroke, and 20+ other neurological conditions.

Presented By Our Partners

For the estimated 50 million Americans living with neurological conditions that affect mobility, walking is not a given. It is a daily negotiation with a nervous system that has lost the ability to reliably coordinate muscle activation. Foot drop, where the brain’s signal to lift the foot during the swing phase of walking fails to reach the ankle dorsiflexors, turns every step into a fall risk. Spasticity, where muscles contract involuntarily and resist stretching, transforms the simple act of walking into an exhausting battle against one’s own body.

A 2020 Cochrane systematic review by Mehrholz et al. analyzed 62 randomized controlled trials involving 2,440 stroke survivors and found that electromechanical assisted gait training combined with physiotherapy doubled the odds of achieving independent walking (OR = 2.01, 95% CI: 1.51 to 2.69, p < 0.00001) compared to physiotherapy alone. A separate 2020 meta analysis by da Cunha et al. in Annals of Physical and Rehabilitation Medicine examined 14 RCTs involving 1,115 participants and found that functional electrical stimulation (FES) of the peroneal nerve improved gait speed when combined with supervised exercise. The evidence is clear: electrical stimulation of weakened muscles, applied at the right time during the gait cycle, can restore functional walking in people with neurological motor impairments.

The Cionic Neural Sleeve 2 represents the most advanced consumer implementation of this principle. It is not a laboratory device or a clinic bound therapy tool. It is a wearable garment, a full leg sleeve embedded with sensors and stimulation electrodes, powered by AI that detects gait phase in real time and delivers precisely timed functional electrical stimulation to the muscles that need it. Cleared by the FDA as a Class II medical device in September 2025, it is the only wearable that simultaneously activates weakened muscles and relaxes spastic muscles, addressing the two primary motor impairments that destroy walking ability in neurological disease.

What Is the Cionic Neural Sleeve 2?

The Cionic Neural Sleeve 2 is a full leg wearable garment that looks like a compression sleeve with embedded electronics. Integrated sensors detect the wearer’s gait phase (stance, swing, heel strike, toe off) in real time, and an AI algorithm determines which muscles need activation and which need relaxation at each moment of the walking cycle. Functional electrical stimulation (FES) electrodes embedded in the fabric deliver precisely timed stimulation to the appropriate muscle groups, compensating for the neural signals that the brain can no longer reliably deliver.

The device’s proprietary “MultiStim” technology is what distinguishes it from conventional FES devices. Traditional FES devices stimulate one muscle group at a time, typically the ankle dorsiflexors for foot drop. The Neural Sleeve 2 can simultaneously activate muscle movement (e.g., lifting the foot during swing phase) and relax spastic muscles (e.g., reducing calf muscle spasticity that resists dorsiflexion), addressing both the weakness and the involuntary resistance that characterize neurological gait disorders. The AI continuously adapts the stimulation parameters based on real time sensor feedback, adjusting to the wearer’s changing gait patterns throughout the day.

The sleeve connects to a companion app that provides gait analytics, walking metrics, and stimulation adjustments. The system is designed for all day wear during normal daily activities, not just during therapy sessions. It is available through a subscription model: $260/month in the first year with reduced rates in subsequent years, with the subscription covering the device, all software updates, and ongoing technical support.

The Science Behind AI Powered Functional Electrical Stimulation

Functional electrical stimulation works by delivering controlled electrical pulses to muscles through surface electrodes, causing the muscles to contract in a pattern that mimics normal voluntary movement. In healthy walking, the brain sends precisely timed motor commands through the spinal cord to the leg muscles: the hip flexors initiate the swing phase, the dorsiflexors lift the foot to clear the ground, the quadriceps extend the knee for heel strike, and the calf muscles push off for propulsion. When neurological disease disrupts these commands, FES provides an external substitute.

According to PubMed, the Mehrholz et al. 2020 Cochrane review of 62 RCTs established that combining electrical stimulation based gait training with physiotherapy significantly improved the odds of independent walking (OR = 2.01, high quality evidence). The review calculated a number needed to treat of eight: for every eight patients who received electromechanical assisted gait training, one additional patient achieved independent walking who would not have done so with physiotherapy alone. People in the first three months after stroke and those who were non ambulatory at baseline benefited most.

The da Cunha et al. 2020 meta analysis of 14 RCTs found that FES applied to the peroneal nerve improved gait speed when combined with supervised physiotherapy. The meta analysis also found improvements in ankle dorsiflexion, balance, and functional mobility, though the quality of evidence was rated as low and heterogeneity was high across studies.

What makes the Cionic Neural Sleeve 2 different from the FES devices studied in these trials is the AI component. Traditional FES devices use fixed stimulation patterns triggered by simple sensors (foot switches, tilt sensors). The Neural Sleeve 2 uses machine learning algorithms that analyze the wearer’s movement patterns in real time and continuously optimize stimulation timing, intensity, and muscle targeting. This adaptive approach can theoretically compensate for the variability inherent in neurological gait disorders, where muscle strength, spasticity, and fatigue change throughout the day and across different activities.

Within Healthcare Discovery‘s longevity framework, neurodegenerative disease is one of the Four Shadows threatening healthspan. While the Neural Sleeve 2 does not treat the underlying neurological disease, it directly addresses one of its most devastating functional consequences: the loss of independent walking. The ability to walk independently is not merely a mobility metric. It is a predictor of cognitive health, social engagement, cardiovascular fitness, and overall survival in aging and neurologically impaired populations. That is the science. Here is how the Cionic Neural Sleeve 2 applies it.

What the Cionic Neural Sleeve 2 Does Well

The simultaneous activation and spasticity management is the Neural Sleeve 2’s defining technological achievement. Spasticity and weakness are not independent problems in neurological disease; they interact. A spastic calf muscle resists the ankle dorsiflexion that the weakened tibialis anterior is trying to produce. Traditional FES devices that only activate the weak muscle must overcome the spastic resistance with stronger stimulation, which is uncomfortable and energy inefficient. By simultaneously relaxing the spastic muscle and activating the weak muscle, the Neural Sleeve 2 achieves more natural movement at lower stimulation intensities.

The all day wearability transforms FES from a therapy session intervention into a continuous mobility aid. Traditional FES devices are used during structured walking training sessions, typically 20 to 60 minutes under clinical supervision. The Neural Sleeve 2 is designed to be worn throughout the day during all weight bearing activities: walking at home, navigating the workplace, shopping, exercising, and managing stairs. This continuous use model means the device supports mobility during the actual daily activities where walking ability matters most, not just during a clinical hour.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The company reports a 94% gait improvement rate in clinical trials and over 2 million hours of real world use across its user base. The FDA Class II 510(k) clearance (September 2025) provides regulatory validation that the device meets safety and effectiveness standards for its intended use. For clinicians, the FDA clearance converts the Neural Sleeve from an experimental technology into a prescribable medical device that can be incorporated into rehabilitation treatment plans with regulatory confidence.

Pricing, Access, and Practical Realities

The Cionic Neural Sleeve 2 operates on a subscription model: $260/month during the first year, with reduced rates in subsequent years. First year total cost is approximately $3,120. The subscription includes the device hardware, all software and AI algorithm updates, technical support, and app access. There is no separate device purchase; the subscription is the complete cost of access.

This pricing model reflects the device’s clinical positioning. For comparison, traditional clinic based FES therapy sessions cost $100 to $300 per visit, and patients typically require multiple sessions per week for months. A physical therapy program for gait rehabilitation can easily exceed $5,000 to $10,000 over a treatment course. The Neural Sleeve 2’s $3,120 annual cost, providing continuous all day mobility support, represents a different value equation than episodic clinical therapy.

The Cionic Neural Sleeve 2 is FDA cleared as a Class II medical device (510(k) clearance, September 2025). This is the standard regulatory pathway for medical devices that have a substantially equivalent predicate device. It is HSA, FSA, and HRA eligible. The company does not operate through an affiliate or retail model; the device is accessed through Cionic directly, with clinical support teams assisting with fitting, calibration, and ongoing optimization.

Who the Cionic Neural Sleeve 2 Is Best For

The Neural Sleeve 2 is designed for individuals with neurological conditions that impair walking ability. The company lists over 20 qualifying conditions including multiple sclerosis, cerebral palsy, stroke, spinal cord injury, traumatic brain injury, Parkinson’s disease, and other conditions affecting lower extremity motor control. Individuals with foot drop, spasticity, or generalized lower extremity weakness from neurological causes represent the primary user population.

People who are ambulatory but impaired, those who can walk but with difficulty, fatigue, or increased fall risk, are the strongest candidates. The device is designed to augment existing walking ability, not to enable walking in individuals who are completely non ambulatory. Users whose neurological condition is stable or slowly progressive (as opposed to rapidly deteriorating) will benefit from the AI’s ability to adapt to gradual changes in motor function over time.

Those who may not be candidates include individuals who are completely unable to bear weight on their legs, people whose mobility impairment is primarily orthopedic rather than neurological (joint replacements, fractures, severe arthritis), and individuals with implanted electronic devices (pacemakers, deep brain stimulators) that could interact with the electrical stimulation. Anyone considering the Neural Sleeve should consult with their neurologist or rehabilitation physician to determine candidacy based on their specific condition and functional status.

How the Cionic Neural Sleeve 2 Compares

The Cionic Neural Sleeve 2 has no direct consumer competitor. It is the only FDA cleared wearable that combines AI powered gait detection, multi muscle functional electrical stimulation, and simultaneous spasticity management in a wearable garment format.

Traditional single channel FES devices (Bioness L300 Go, WalkAide) stimulate the peroneal nerve to address foot drop specifically. They are FDA cleared, well established, and less expensive (typically $4,000 to $6,000 purchase). However, they address only one component of the gait cycle (ankle dorsiflexion) and do not manage spasticity. For individuals whose sole impairment is foot drop without spasticity, a single channel FES device may be sufficient. For individuals with multi muscle involvement and spasticity, the Neural Sleeve 2 provides broader intervention.

Ankle foot orthoses (AFOs) are the most common non electronic intervention for foot drop, using a rigid or semi rigid brace to passively maintain ankle position. AFOs are inexpensive ($100 to $500), require no battery, and have decades of clinical use. However, they provide passive support without muscle activation, do not address spasticity, and can cause skin irritation and discomfort with all day wear. The Neural Sleeve 2 actively stimulates muscles, potentially maintaining or improving muscle strength over time rather than allowing further atrophy.

Robotic exoskeletons (ReWalk, Ekso) provide powered walking for individuals with severe mobility impairment, including complete paraplegia. They are substantially more expensive ($70,000 to $150,000), require training, and are designed for structured walking sessions rather than all day wear. The Neural Sleeve 2 occupies the space between passive orthoses and powered exoskeletons: active muscle stimulation in a lightweight, wearable format suitable for daily life.

Limitations and Open Questions

The subscription model creates an ongoing financial commitment that may be challenging for individuals on disability income or fixed retirement budgets. At $260/month, the device represents a significant recurring expense that must be weighed against other medical costs. Insurance coverage for the Neural Sleeve 2 is evolving; as a newly FDA cleared device, coverage determinations are still being established by individual payers.

The AI adaptation capability, while technologically impressive, introduces a dependence on the company’s continued operation and software support. If Cionic were to discontinue the product or cease software updates, users would lose the adaptive intelligence that distinguishes the device from simpler FES systems. The subscription model means users never own the hardware outright, creating a dependency on the company’s business continuity.

Individual response to FES varies significantly based on the nature and severity of the neurological condition, the degree of preserved motor unit availability, skin sensitivity, and the specific muscles involved. Not all users will experience the 94% gait improvement rate reported in trials; some conditions and presentations may be less responsive to surface electrical stimulation. Users should undergo a clinical assessment and trial period before committing to the subscription. The long term effects of daily, all day FES use over years, including potential effects on muscle fatigue, skin integrity, and neural adaptation, are still being characterized as the device is relatively new to market.

What This Means for Your Health

The ability to walk is one of the most fundamental determinants of health, independence, and quality of life. For people with neurological conditions, the loss of walking ability triggers a cascade of secondary health consequences: cardiovascular deconditioning from reduced activity, bone density loss, increased fall risk, social isolation, depression, and accelerated cognitive decline. Restoring or preserving walking ability is not merely a mobility goal. It is a systemic health intervention that touches every dimension of the longevity equation.

Within HealthcareDiscovery.ai’s Five Pillars framework, the Cionic Neural Sleeve 2 addresses the Movement pillar at its most critical level: maintaining the ability to move through space independently. For individuals with neurological conditions, this single capability enables everything else. You cannot maintain cardiovascular fitness without walking. You cannot sustain social connections without mobility. You cannot access the healthcare, nutrition, and community resources that support healthspan without the ability to get out of a chair and move through the world.

The Neural Sleeve 2 represents a genuine advance in what wearable technology can do. Not measure. Not track. Not analyze. Do. It activates muscles. It relaxes spasticity. It adapts in real time. It wraps around a leg and makes walking possible for people whose nervous systems can no longer do it alone. In a consumer health technology landscape dominated by devices that monitor the healthy, the Cionic Neural Sleeve 2 stands apart as a device that restores function to the impaired. For the millions of people navigating life with neurological conditions, that difference is not incremental. It is transformative.

Frequently Asked Questions

What conditions does the Cionic Neural Sleeve 2 treat?
The Neural Sleeve 2 is FDA cleared for individuals with neurological conditions affecting lower extremity mobility, including multiple sclerosis, cerebral palsy, stroke, spinal cord injury, traumatic brain injury, Parkinson’s disease, and over 20 other neurological conditions. The device addresses gait impairments including foot drop, spasticity, and generalized lower extremity weakness. Candidacy should be assessed by a neurologist or rehabilitation physician based on individual functional status.

How much does the Cionic Neural Sleeve 2 cost?
The device operates on a subscription model at $260/month during the first year ($3,120 annually), with reduced rates in subsequent years. The subscription includes the hardware, all software and AI updates, technical support, and app access. The device is HSA, FSA, and HRA eligible. Insurance coverage is evolving as the device is newly FDA cleared. For comparison, traditional clinic based FES therapy and physical therapy programs often exceed $5,000 to $10,000 per treatment course.

Is the Cionic Neural Sleeve 2 FDA cleared?
Yes. The Neural Sleeve 2 received FDA 510(k) clearance as a Class II medical device in September 2025. This means the FDA reviewed the device and determined it meets safety and effectiveness standards based on substantial equivalence to predicate devices. It is the first and only FDA cleared wearable that simultaneously activates muscle movement and manages spasticity using AI powered functional electrical stimulation.

Can I wear the Neural Sleeve all day?
Yes. The device is designed for all day wear during normal daily activities including walking at home, at work, during errands, and during exercise. This continuous use model distinguishes it from traditional FES devices that are typically used during structured therapy sessions. The sleeve is designed to fit under clothing and is constructed from comfortable, washable fabric with embedded electronics.

How does the AI adapt to my walking?
The Neural Sleeve 2 uses machine learning algorithms that analyze your gait in real time through embedded sensors. The AI detects your current gait phase (stance, swing, heel strike, toe off) and continuously adjusts stimulation timing, intensity, and muscle targeting based on your movement patterns. The system adapts to changes throughout the day (fatigue, terrain, speed) and over weeks and months as your condition evolves. This adaptive capability means the device’s support changes with you rather than requiring manual reprogramming.

What is the difference between the Neural Sleeve and a traditional AFO brace?
An ankle foot orthosis (AFO) passively holds the ankle in position using a rigid or semi rigid brace ($100 to $500). It prevents foot drop but does not activate muscles, manage spasticity, or adapt to changing conditions. The Neural Sleeve 2 ($260/month) actively stimulates weakened muscles, simultaneously relaxes spastic muscles, and uses AI to continuously optimize stimulation. Active muscle stimulation may help maintain or improve muscle strength over time, while passive bracing allows muscles to further atrophy. The Neural Sleeve is a medical device requiring clinical assessment; an AFO can be obtained through most orthotists.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.